Evidence map›Paper›PMID 32211604›Full record

ReviewMaterials today. Bio2020

Materials and manufacturing perspectives in engineering heart valves: a review.

F Oveissi, S Naficy, A Lee, D S Winlaw, F Dehghani

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 138 citations in OpenAlex.

  1. Review
  2. Innovation and Challenges in Materials for Transcatheter Aortic Valves.Journal of cardiovascular translational research · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

F OveissiSchool of Chemical and Biomolecular Engineering, The University of Sydney, Sydney, New South Wales, 2006, Australia.
S NaficySchool of Chemical and Biomolecular Engineering, The University of Sydney, Sydney, New South Wales, 2006, Australia.
A LeeSchool of Chemical and Biomolecular Engineering, The University of Sydney, Sydney, New South Wales, 2006, Australia.
D S WinlawDiscipline of Child and Adolescent Health, Sydney Medical School, Faculty of Health and Medicine, The University of Sydney, New South Wales, 2006, Australia.
F DehghaniSchool of Chemical and Biomolecular Engineering, The University of Sydney, Sydney, New South Wales, 2006, Australia.
The University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Valvular heart diseases (VHD) are a major health burden, affecting millions of people worldwide. The treatments for such diseases rely on medicine, valve repair, and artificial heart valves including mechanical and bioprosthetic valves. Yet, there are countless reports on possible alternatives noting long-term stability and biocompatibility issues and highlighting the need for fabrication of more durable and effective replacements. This review discusses the current and potential materials that can be used for developing such valves along with existing and developing fabrication methods. With this perspective, we quantitatively compare mechanical properties of various materials that are currently used or proposed for heart valves along with their fabrication processes to identify challenges we face in creating new materials and manufacturing techniques to better mimick ​the performance of native heart valves.

Indexed as

3D printingBiofabricationBiomaterialsdECM, decellularized extracellular matrixElectrospinningePTFE, expanded PTFEE, Young's modulusGal, galactose-α1,3-galactoseGelMa, gelatin methacrylateHA, hyaluronic acidHAVIC, human aortic valvular interstitial cellsMA-HA, methacrylated hyaluronic acidNeuGc, N-glycolylneuraminic acidP4HB, poly(4-hydroxybutyrate)PAAm, polyacrylamidePCE, polycitrate-(ε-polypeptide)PCL, polycaprolactonePEGDA, polyethylene glycol diacrylatePEG, polyethylene glycolPE, polyethylenePGA, poly(glycolic acid)PHA, poly(hydroxyalkanoate)PLA, polylactidePMMA, poly(methyl methacrylate)PPG, polypropylene glycolPTFE, polytetrafluoroethylenePU, polyurethaneSIBS, poly(styrene-b-isobutylene-b-styrene)SMC, smooth muscle cellsValvular heart diseasesVHD, valvular heart diseaseVIC, aortic valve leaflet interstitial cellsxSIBS, crosslinked version of SIBSα-SMA, alpha-smooth muscle actin

Identifiers

PMID32211604
PMCPMC7083765
OpenAlexW2993456875

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.